X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

GlaxoSmithKline Vaccine Manufacturing Plant, St-Amand-Les-Eaux, France

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Europe, Projects

GSK Biologicals, the vaccine division of the pharmaceutical and healthcare company GlaxoSmithKline (GSK), announced its decision to build a new production facility in St-Amand-Les-Eaux, France on 29 September 2006. The new plant, currently under construction, will increase the company’s annual production capacity in formulation, filling, freeze-drying and packaging for paediatric and adult vaccines, to more than 300 million doses.

GSK will invest more than €500m in this facility located in Northern France to strengthen the company’s global vaccine manufacturing network. The new investment was called for as the company’s biologicals division plans to launch five major new vaccines by 2011.

The contract for the St-Amand-Les-Eaux plant’s architectural design was awarded to Alain Farel Architects. Technical services, including electrical and mechanical engineering for the new plant, are being provided by Imtech NV.

GSK expects to complete the construction and start production at the facility by 2011. Once fully operational, the new plant is expected to employ about 750 people.

Location and vaccines produced

GSK’s new project in St-Amand-Les-Eaux was approved by the French authorities as part of their initiative launched in 2005 to improve the consideration for the competitive stakes of companies, by implementation of seven competitive clusters exclusively devoted to the bio-pharmaceuticals industry.

“The investment was called for as the company’s biologicals division plans to launch five new vaccines by 2011.”

GSK will benefit from the French government’s tax concessions for the company’s investment.

Cervarix, GSK’s anti-cervical cancer vaccine, is the main vaccine that will be manufactured at the new site. The St-Amand-les-Eaux site has been chosen as it is close to Brussels, where GSK has a production unit for the active ingredient used in the Cervarix vaccine.

Other vaccines that the St-Amand-Les-Eaux plant will help to produce include the company’s new meningitis vaccines, and two unnamed vaccines – one, a seasonal influenza vaccine and the other, a paediatric vaccine to protect against non-typeable Haemophilus influenzae and streptococcus pneumonia.

While GSK expects to receive US Food and Drug Administration approval for Cervarix towards the end of 2009, the new plant will be made available to meet the projected demand for the cancer-fighting drug.

Synflorix, GSK’s new drug against meningitis was authorised in Europe in March 2009, and could be one of the vaccines that the proposed plant may produce.

Production facilities

The project will include building a number of facilities to assist in the production of GSK’s innovative new vaccines.

“To increase its global vaccines supplying capacity, GSK has been developing a global manufacturing network.”

A freeze-drying plant to be built in the new facility will convert liquid vaccines into a solid powder to enhance the shelf-life and stability of the vaccines. A liquid plant will be installed at the site for filling syringes and vials. Apart from these, the site will also house quality control laboratories, a packing plant and warehouse, and a power plant.

Background information

To increase its global vaccines supplying capacity, GSK has been developing a global manufacturing network based on three major hubs in Europe, North America and Asia. In July 2005, the company invested €94.3m to double production in its Dresden, Germany plant.

In June 2006, it announced a S$300m (about €150m) investment in a new vaccine manufacturing plant in Singapore for production of paediatric vaccines, the company’s first plant in the country.

Tags: Europe
Previous Post

Cordis Corporation Manufacturing Plant, Cashel, Co Tipperary, Ireland

Next Post

Polpharma Dry Forms II Production Facility, Poland

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Europe

Chemspec Europe 2018 in Cologne closes with a record in visitor numbers

6th July 2018
Next Post

Polpharma Dry Forms II Production Facility, Poland

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In